Endocannabinoids through activation of cannabinoid type 1 receptor (CB1R) promotes CNS activation and food intake leading to MetS; therefor inhibition of CB1R by selective blocker is used in treating obesity and MetS.13 This evidence concerns the gene CNR1 and metabolic syndrome.